US Pharma MarketingThe post FDA approval of mFLUSIVA highlights Moderna’s position in mRNA market appeared first on Clinical Trials Arena.
FDA approval of mFLUSIVA highlights Moderna’s position in mRNA market
mFLUSIVA is now the first and only mRNA standalone seasonal influenza vaccine on the market, marking a major advancement for the field. The post FDA approval of mFLUSIVA highlights Moderna’s position in mRNA market appeared first on Clinical Trials Arena .
mFLUSIVA is now the first and only mRNA standalone seasonal influenza vaccine on the market, marking a major advancement for the field.
Source: Clinical Trials Arena